Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-11-Speech-2-371-250"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech²
dcterms:Date	"2012-09-11"^^xsd:date²
dcterms:Is Part Of	lp_eu:Explanations of vote²
dcterms:Language	"fr"^^xsd:language²
lpv:document identification number	"en.20120911.32.2-371-250"²
lpv:hasSubsequent	lp_eu:2012-09-11-Speech-2-371-375²
lpv:speaker	lp:Brice Hortefeux²
lpv:spokenAs	unknown; Union pour un Mouvement Populaire (2011-03-24--2014-06-30)^3,3 member; REGI (2012-01-19--2014-06-30)^3,3 member; EPP (2011-03-24--2014-06-30)^3,3
lpv:translated text	"In 2010, the European institutions agreed to revise the rules regulating pharmacovigilance with a view to implementing the legislation in 2012. This new legislation reinforces the coordinating role of the European Medicines Agency and improves the ‘signal’-based detection system that reveals potential problems and the system for follow-up at European level. Since then, the Mediator scandal has led us to reinforce once again the pharmacovigilance measures. That is the conclusion that emerges from the analyses (stress tests) carried out following the scandal. The European Parliament has set itself the objective of improving the protection of European citizens’ health. In order to do this, it estimates that we must redouble our efforts in the detection of risks and prevent them as much as possible. In order to be more efficient, however, better cooperation at European level is necessary."@en¹

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph